Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Easing the PPE Strain During the Pandemic

During the early days of the pandemic, one of the healthcare community’s challenges was a critical lack of PPE to fight the coronavirus. Ryan Madewell, Director of Environmental Services at Hunt Regional Healthcare for Vanguard Resources, spoke about this problem and how Surfacide’s UV-C solutions helped keep front-line workers and patients safe. Even before…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Easing the PPE Strain During the Pandemic

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

During the early days of the pandemic, one of the healthcare community’s challenges was a critical lack of PPE to fight the coronavirus. Ryan Madewell, Director of Environmental Services at Hunt Regional Healthcare for Vanguard Resources, spoke about this problem and how Surfacide’s UV-C solutions helped keep front-line workers and patients safe.

Even before hospitals began to fill up with coronavirus-infected patients, Madewell said the challenge was always how to get more PPE to prepare for those patients.

“We began researching how we were going to be able to get through if we weren’t able to get more PPE or if there was a limited supply, so we landed on UV light. We already had the Surfacide. We’ve been happy with our Helios system for the past seven years. Finding another use for it was great,” he said.

Due to the infectious nature of the virus, Madewell said the situation provided a dual challenge. While never transitioning entirely away from patient safety, it became essential to protect healthcare workers and employees from the virus.

“The fact [was] we had a limited amount of specifically N95s, but disinfectants [also] became hard to come by,” Madewell said. “We had to make some changes and readdress what our processes were going to be, and we made sure everybody stayed safe and had what they needed to do their job.”

When the CDC provided guidance saying UV-C could be used in an emergency to reprocess N95 respirators, and Madewell and his team put a plan together to use Surfacide.

“Not long after we started trial runs, and began reprocessing when it was necessary,” Madewell said. “And we’ve been doing it ever since.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512